How much does adagrasib cost? Is it covered by medical insurance?

Adagrasib (Adagrasib), a drug with significant anti-tumor activity, is gradually becoming an important weapon in the treatment of specific types of cancer. It specifically targets patients with non-small cell lung cancer (NSCLC) whose tumors carry the abnormal KRAS G12C gene and have received at least one prior therapy. This genetic abnormality plays a key role in the development of cancer, and adagrasib inhibits the growth of cancer cells by precisely interfering with the function of this abnormal gene.

Not only that, adagrasib has also shown significant efficacy in the treatment of colorectal cancer. When used in combination with cetuximab, it is effective against disseminated colorectal cancer in tumors with KRAS G12C gene abnormalities that have been treated with other cancer drugs such as fluoropyrimidine, oxaliplatin and irinotecan. This combination therapy provides patients with new treatment strategies, especially when traditional treatments have limited effectiveness or are resistant.

Adagrasib has a unique mechanism of action. It can gradually weaken the vitality of cancer cells by interfering with the growth signals of cancer cells, and ultimately promote the death of cancer cells. As an anti-tumor drug, it not only demonstrates powerful anti-cancer effects, but also brings new hope to patients facing a difficult battle against cancer.

Adagrasib is not currently on the market in China, so it cannot be included in domestic medical insurance reimbursement items. It is understood that the first generic drug of adagrasibu has recently been launched in Laos. This world-first initiative brings hope to the families of patients who have given up treatment due to the high price of the original drug. The launch of the Lao version of the generic version of adagrasibu broke the price monopoly of the original drug and significantly reduced the cost of treatment from 200,000 yuan per month to 8,000 to 9,000 yuan. If patients have more questions about adagrasib, please consult a regular overseas medical consultation agency.